These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30015487)

  • 41. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases.
    Wang Z; Yin L; Xiong Z; Huang F; Yang N; Jiang F; Li H; Cui Y; Ren J; Cheng Z; Jia K; Lu T; Zhu J; Hu Q; Chen Y
    J Med Chem; 2023 Aug; 66(15):10824-10848. PubMed ID: 37478496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.
    Yang CY; Qin C; Bai L; Wang S
    Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
    Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
    ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
    Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
    J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives.
    Akawa OB; Soremekun OS; Olotu FA; Solima MES
    Curr Pharm Biotechnol; 2022; 23(3):444-456. PubMed ID: 33749556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of a Series of
    Harrison LA; Atkinson SJ; Bassil A; Chung CW; Grandi P; Gray JRJ; Levernier E; Lewis A; Lugo D; Messenger C; Michon AM; Mitchell DJ; Preston A; Prinjha RK; Rioja I; Seal JT; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
    J Med Chem; 2021 Aug; 64(15):10742-10771. PubMed ID: 34232650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors.
    Koravovic M; Mayasundari A; Tasic G; Keramatnia F; Stachowski TR; Cui H; Chai SC; Jonchere B; Yang L; Li Y; Fu X; Hiltenbrand R; Paul L; Mishra V; Klco JM; Roussel MF; Pomerantz WC; Fischer M; Rankovic Z; Savic V
    Eur J Med Chem; 2023 May; 251():115246. PubMed ID: 36898329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
    Yoo M; Yoo M; Kim JE; Lee HK; Lee CO; Park CH; Jung KY
    Arch Pharm Res; 2018 Jan; 41(1):46-56. PubMed ID: 29103140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pyronaridine as a Bromodomain-Containing Protein 4-
    Ibrahim MAA; Abdelhamid MMH; Abdeljawaad KAA; Abdelrahman AHM; Mekhemer GAH; Sidhom PA; Sayed SRM; Paré PW; Hegazy MF; Shoeib T
    Molecules; 2023 Jul; 28(15):. PubMed ID: 37570684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues.
    Jiang H; Xing J; Wang C; Zhang H; Yue L; Wan X; Chen W; Ding H; Xie Y; Tao H; Chen Z; Jiang H; Chen K; Chen S; Zheng M; Zhang Y; Luo C
    Org Biomol Chem; 2017 Nov; 15(44):9352-9361. PubMed ID: 29087414
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
    Zhao L; Wang Y; Cao D; Chen T; Wang Q; Li Y; Xu Y; Zhang N; Wang X; Chen D; Chen L; Chen YL; Xia G; Shi Z; Liu YC; Lin Y; Miao Z; Shen J; Xiong B
    J Med Chem; 2015 Feb; 58(3):1281-97. PubMed ID: 25559428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening.
    Kim YH; Kim M; Yoo M; Kim JE; Lee HK; Heo JN; Lee CO; Yoo M; Jung KY; Yun CS; Moon SW; Chang HK; Chung CW; Pyo S; Choi SU; Park CH
    Biochem Biophys Res Commun; 2018 Sep; 503(2):882-887. PubMed ID: 29928885
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective inhibition of BET bromodomains.
    Filippakopoulos P; Qi J; Picaud S; Shen Y; Smith WB; Fedorov O; Morse EM; Keates T; Hickman TT; Felletar I; Philpott M; Munro S; McKeown MR; Wang Y; Christie AL; West N; Cameron MJ; Schwartz B; Heightman TD; La Thangue N; French CA; Wiest O; Kung AL; Knapp S; Bradner JE
    Nature; 2010 Dec; 468(7327):1067-73. PubMed ID: 20871596
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
    Hu J; Wang Y; Li Y; Cao D; Xu L; Song S; Damaneh MS; Li J; Chen Y; Wang X; Chen L; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2018 Apr; 150():156-175. PubMed ID: 29525435
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors.
    Noguchi-Yachide T; Sakai T; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem; 2015 Mar; 23(5):953-9. PubMed ID: 25678016
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of novel BRD4 inhibitors by high-throughput screening, crystallography, and cell-based assays.
    Sun Z; Zhang H; Chen Z; Xie Y; Jiang H; Chen L; Ding H; Zhang Y; Jiang H; Zheng M; Luo C
    Bioorg Med Chem Lett; 2017 May; 27(9):2003-2009. PubMed ID: 28347667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site.
    Liu Z; Li Y; Chen H; Lai HT; Wang P; Wu SY; Wold EA; Leonard PG; Joseph S; Hu H; Chiang CM; Brasier AR; Tian B; Zhou J
    J Med Chem; 2022 Feb; 65(3):2388-2408. PubMed ID: 34982556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.